<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04271514</url>
  </required_header>
  <id_info>
    <org_study_id>RPT193-01</org_study_id>
    <nct_id>NCT04271514</nct_id>
  </id_info>
  <brief_title>A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation, Multiple-dose Escalation, and Food Effect Study of RPT193 in Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RAPT Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RAPT Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a first-in-human, 3-part, multi-center, Phase 1, randomized, double-blind,
      placebo-controlled study with RPT193 in up to 64 healthy male and female subjects and 30 male
      and female patients with atopic dermatitis. RPT193 is an orally-available, potent, and
      selective antagonist of CCR4.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>up to Day 16 (Part A: SAD); up to Day 22 (Part B: MAD); up to Day 43 (Part C)</time_frame>
    <description>Number of participants with abnormal laboratory values and/or adverse events that are related to treatment</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Single Dose Escalation Part A - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of RPT193 will be administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose Escalation Part A - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Escalation Part B - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing doses of RPT193 will be administered once/day for 7 days to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Dose Escalation Part B - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered once/day for 7 days to healthy volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Part C - active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT193 will be administered daily for 28 days to patients with atopic dermatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Part C - placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo will be administered daily for 28 days to patients with atopic dermatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RPT193</intervention_name>
    <description>Antagonist of the CCR4 chemokine receptor</description>
    <arm_group_label>Expansion Part C - active</arm_group_label>
    <arm_group_label>Multiple Dose Escalation Part B - active</arm_group_label>
    <arm_group_label>Single Dose Escalation Part A - active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Expansion Part C - placebo</arm_group_label>
    <arm_group_label>Multiple Dose Escalation Part B - placebo</arm_group_label>
    <arm_group_label>Single Dose Escalation Part A - placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Selected Inclusion Criteria:

        Parts A &amp; B:

          -  Healthy male or female

          -  18-55 years of age, inclusive

          -  At least 50 kg in weight

          -  BMI: 18.0-30.0 kg/m2, inclusive

        Part C:

          -  Male or female with atopic dermatitis

          -  18-65 years of age, inclusive

          -  BMI 18.0-35.0 kg/m2, inclusive

          -  Body surface area (BSA) with AD involvement ≥10%

          -  Eczema Area and Severity Index (EASI) score ≥12

          -  Validated Investigator's Global Assessment (vIGA) ≥3

          -  History of inadequate response to treatment with topical medications, such as
             corticosteroids or calcineurin inhibitors, or patients for whom topical treatments are
             otherwise medically inadvisable

        Selected Exclusion Criteria:

        Parts A &amp; B:

          -  Use of tobacco products within 60 days prior to drug administration

          -  History of alcohol abuse or drug addiction

          -  Positive drug and alcohol screen

          -  Participation in a drug study within 60 days prior to drug administration

          -  Donation or loss of more than 100 mL of blood within 60 days prior to drug
             administration.

          -  Donation or loss of more than 1.5 liters of blood (for male subjects) / more than 1.0
             liters of blood (for female subjects) in the 10 months prior to drug administration.

        Part C:

          -  Any serious and/or uncontrolled medical condition

          -  History of alcohol abuse or drug addiction

          -  Positive drug and alcohol screen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Cheng, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RAPT Therepeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clincal Trial Manager</last_name>
    <phone>650-489-9000</phone>
    <email>clinical.trials@rapt.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Perseverance Research Center LLC</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Hank</last_name>
      <phone>480-471-6132</phone>
      <email>nhank@prcresearcheducation.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Vega</last_name>
      <phone>858-278-8470</phone>
      <phone_ext>311</phone_ext>
      <email>carlos@univct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenia Casas, DA, CRC</last_name>
      <phone>305-592-4692</phone>
      <email>lcasas@lenusresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ForCare Clinical Research</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynne Thompson, CCRC</last_name>
      <phone>813-264-2155</phone>
      <email>lthompson@forcaremed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Wallace, CCRC</last_name>
      <phone>317-516-5030</phone>
      <phone_ext>102</phone_ext>
      <email>awallace@ecommunity.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Ormedilla</last_name>
      <phone>504-336-2667</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management,LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Daigle</last_name>
      <phone>504-455-1310</phone>
      <email>wdaigle@clinicaltrialsmgt.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MetroBoston CLinical Partners LLC</name>
      <address>
        <city>Brighton</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stella Schandorf</last_name>
      <phone>617-789-5300</phone>
      <email>stellaschandy@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group LLC</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Swearingen</last_name>
      <phone>212-772-7242</phone>
      <email>aswearingen@sadickdermatology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Central Sooner Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Smith</last_name>
      <phone>405-329-0474</phone>
      <email>ksmith@centralsooner.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unity Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>13118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karina Garcia, CCRC</last_name>
      <phone>512-349-9889</phone>
      <email>karina@driresearchsite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Reyna, LVN</last_name>
      <phone>210-614-5557</phone>
      <email>mreyna@progclin.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PRA</name>
      <address>
        <city>Groningen</city>
        <zip>9728 NZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Radboud Universtiy Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elke de Jong</last_name>
      <phone>31 24 3613724</phone>
      <email>Elke.deJong@radboudumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

